Skip to content

A Post Market Surveillance Study to evaluate the safety and performance of the Vector Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter in real-world settings.

A prospective, multi-center, post-market surveillance (PMS) study to evaluate the safety and performance of The Vector Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter in real-world settings. - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/086349
Enrollment
100
Registered
2025-05-05
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I708- Atherosclerosis of other arteries

Interventions

Intervention1: Vector Percutaneous Transluminal Coronary Angioplasty PTCA Balloon Dilatation Catheter: The Vector PTCA Balloon Catheter is indicated for balloon dilation of the stenotic portion of a c

Sponsors

Dr Ajay Mahajan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient Male & Female both inclusive must be at least 18 years of age at the time of signing the informed consent. Lesion must be successfully crossed with a guide wire without complications with a maximum of five attempts. 2. All patients having acute MI or chronic coronary syndrome irrespective of duration with coronary angiography showing at least one lesion more than 70 percent luminal stenosis. No adhoc angioplasty patients will be enrolled. 3. Subject or legally authorized representative must provide written informed consent prior to any study related procedure. 4. Subject must agree not to participate in any other clinical study during hospitalization for the index procedure to obtain informed Consent. 5. Subjects have at least a single or double vessel coronary artery disease and clinical evidence of ischemic heart disease, such as stable unstable angina or silent ischemia.

Exclusion criteria

Exclusion criteria: 1. Subject with a known hypersensitivity, severe reactions or contraindicated to Aspirin, Heparin, Bivalirudin, antiplatelet medications, or sensitivity to contrast media which cannot be adequately premedicated. 2. Pregnant women. 3. Subject has a known left ventricular ejection fraction LVEF less than 30 percent LVEF may be obtained at the time of index procedure if the value is unknown, if necessary. 4. Patients with severe systemic diseases like renal failure eGFR less than 30 mL/min/m2, uncontrolled diabetes, active infection, respiratory failure or cardiac failure. 5. Patients having no lesion more than 70 percent luminal stenosis will be excluded from study

Design outcomes

Primary

MeasureTime frame
1. Successful delivery, inflation, deflation & withdrawal of balloon. 2. No perforation, flow limiting dissection or reduction into TIMI Flow grade.Timepoint: Immediately after interventional procedure (within 48 hours)

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Ajay Mahajan

Seth GS Medical College and KEM Hospital

drajaymahajan2vvnc@gmail.com9869032639

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026